Opus Genetics Inc
(NAS:IRD)
$
4.075
+0.10 (+2.48%)
Market Cap: 336.46 Mil
Enterprise Value: 277.69 Mil
PE Ratio: 0
PB Ratio: 0
GF Score: 24/100 Opus Genetics Inc at RBC Capital Markets Ophthalmology Conference (Virtual) Transcript
Mar 25, 2026 / 03:45PM GMT
Release Date Price:
$4.75
(+5.32%)
Lisa Walter
RBC Capital Markets Inc - Equity Analyst
Good morning, everyone. I'm Lisa Walter, biotech analyst at RBC Capital Markets. Thanks for joining us at RBC's Ophthalmology Conference. This session, we have George Magrath, Chief Executive Officer of Opus Genetics. George, thanks so much for joining us today. How are you doing?
George Magrath
Opus Genetics Inc - Chief Executive Officer, Director
Doing wonderfully. Thank you, Lisa, and thank you to the RBC team for inviting us.
Questions & Answers
Lisa Walter
RBC Capital Markets Inc - Equity Analyst
Well, it's a pleasure to host you this morning. George, maybe to kick things off, could you maybe give us a big-picture overview of the company and give us an idea about where things stand with your inherited retinal disease programs?
George Magrath
Opus Genetics Inc - Chief Executive Officer, Director
Yeah, totally. I mean, it's a great space to be in right now. A lot of activity in inherited retinal
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |

30-Day 100% money back guarantee
Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot